24 October 2024
The life sciences industry has increasingly tuned its attention to rare diseases, with 143 orphan drugs launched in the U.S. over the past five years, accounting for 53% of the total 268 launches during this period. Despite the growing number of treatments, achieving launch excellence in rare disease market remains an intricate challenge. Traditional pharma product launch strategies used for broad market are often ineffective in this unique landscape. Innovative approaches are essential, and many organizations are harnessing the power of data and analytics to drive success and excellence at every stage of the launch journey.
At Indegene Digital Summit 2024, industry experts Ashish Sharma, Bart Vanmedegael, and Saket Malhotra, all of whom bring extensive launch experience in the rare disease market, shared their insights into how data-driven strategies are transforming the path to launch excellence.
The key highlights from their session are highlighted below.
Key Factors Impacting Rare Disease Drug Launches
Rare disease launches come with unique complexities that sets them apart from other therapeutic areas.
Leveraging predictive analytics to personalize user journeys
Implementing intuitive onboarding processes for seamless navigation
Conducting rigorous usability testing to identify and address potential pain points.
Data-Driven Strategies for Navigating Different Rare Disease Launch Phases
Organizations are adopting a data-first approach to navigate the complexities of launching rare disease therapies. Here’s how they can leverage data and analytics to succeed:
Create a Single Source of Truth with Right Data Sources
Successful launches are built on a foundation of high-quality data. In rare diseases, where traditional large-scale datasets are scarce, the focus must shift to more nuanced, qualitative data. Bringing together diverse data sources—like electronic medical records (EMRs), biomarkers, patient registries, and claims data—into a single source of truth is critical.
“In many cases, you may not have access to competitive insights through traditional channels like claims or real-world data sources. Companies must explore innovative data approaches to gain a deeper understanding of the market”
— Saket Malhotra
Use Diverse Data Sets and Advanced Analytics for Market Sizing and Targeting
Once you identify your diverse data sources, combine them to define your market opportunity. This approach ensures comprehensive coverage of physicians and patient numbers for market sizing and field targeting.
If you're the first entrant in the market, investing in EHR/EMR data can be a game changer since claims data alone may not provide the insights you need. Leverage advanced technologies like AI and machine learning to merge various data sets and fill knowledge gaps, helping identify patient locations and targeting expert centres effectively.
Lastly, prioritize your account targets to guide your territory planning and segmentation. Recognize the factors that can influence your forecasting efforts to make informed decisions about resource allocation and contract negotiations.
“It’s crucial to identify the data set that best matches the therapeutic area you're focused on. Investing time in understanding these data sources is vital to success.”
— Bart Vanmedegael
Leverage Real-World Evidence (rwe) to Engage Payers
Rare disease launches require more than claims data—companies need to present real-world evidence to demonstrate their therapies' value. By integrating clinical data with pathway information, you can make compelling cases to the payers and pharmacy benefit managers (PBMs) as part of your market access strategies.
Additionally, leverage group purchasing organization (gpo) or site-level data to enhance your approach. Combining pre-launch clinical evidence, safety information, and internal datasets with commercial data can significantly boost your payer-Pbm strategies and market penetration.
As you engage with payers, account for the comorbidities and co-medications affecting your target patient population. This presents a unique challenge, especially with patients receiving therapies for multiple indications.
“Therapy evaluations often focus on quality of life, and it's crucial to effectively present and quantify this data. To achieve this, prioritize gathering robust real-world evidence.”
— Bart Vanmedegael
Focus on the Value of Care for Market Access and Reimbursement
Saket emphasized how companies can harness real-world data to pinpoint where patients are concentrated and craft targeted market access strategies for payers and PBMs. By integrating external payer-level information, companies can tailor their access strategies for various payer groups, streamlining the reimbursement process.
Convincing payers of the value of your therapies is also crucial in the launch journey. With payers increasingly focused on budget impacts, using data analytics to forecast financial implications over the next three to five years can make a significant difference. With risk-based and value-based agreements, you must find the right balance in your forecasts. Underestimating potential benefits may lead to missed opportunities, while overestimating can keep your therapies off the market.
Additionally, shift the concept from cost of care to value of care. Together with the payer, you can redefine strategies that demonstrate the true value of your therapies, emphasizing patient outcomes beyond just costs.
“Market prognosis and funding are crucial. For instance, increasing funding for high-cost therapies significantly enhances patient access and impacts the average price per standard treatment, an area that is increasingly attracting attention.”
— Ashish Sharma
Adopt a Data-Driven Omnichannel Strategy for Personalized Engagement
Becoming truly patient-centric or patient-obsessed requires a focus on personalized experiences, and an effective omnichannel engagement strategy that combines real-world and digital data can be the key. By stacking your data, you can uncover new dimensions and insights that ready, out-of-the-box data or analysis alone can't offer. Utilizing diverse data sources like EMRs and social media insights can further enhance this approach.
By utilizing predictive analytics, you can anticipate potential exacerbations or worsening symptoms, enabling proactive support and tailored interventions, and improving patient outcomes.
“As we shift our focus from physicians to patients, creating personalized experiences becomes increasingly important.”
— Saket Malhotra
Utilize Feedback Loop and Real-time Insights for Optimizing Post-Launch Success
The launch is just the beginning. Continuous monitoring of real-world performance, patient feedback, and market trends allows companies to adapt their strategies in near real-time. Social media and other digital touchpoints offer valuable insights, helping companies track competition and refine their approaches post-launch.
“The launch is a moment of celebration, but it's also the time to validate your assumptions and adjust as necessary.”
— Bart Vanmedegael
Conclusion
In this evolving rare disease launches landscape, data and analytics is key to achieving success. Whether you're generating real-world evidence, streamlining pharma market access, or creating personalized customer experiences, advanced technologies like generative AI and machine learning are invaluable. By tapping into these tools, companies can gain better insights, refine their pharma product launch strategies, and ultimately enhance patient outcomes, paving way for launch excellence and lasting impact in the market.
